| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
(+)-Di-p-toluoyl-D-tartaric acid is a chiral resolving agent and enzyme inhibitor rather than a direct pharmacological agent. As a resolving agent, it does not have specific biological receptors as its primary targets. The compound's mechanism of action in chiral resolution involves formation of diastereomeric salts with racemic mixtures, enabling separation of enantiomers. The compound's tartaric acid scaffold is a privileged structure in chiral chemistry. Its primary applications are as a chiral resolving agent for organic synthesis and as an enzyme inhibitor for research purposes.
|
|---|---|
| ln Vitro |
Compound A is related to rivastigmine USP.
In vitro, (+)-di-p-toluoyl-D-tartaric acid is used as a biochemical reagent and organic compound for biomedical research. It is used as a chiral resolving agent for the separation of enantiomers and as an enzyme inhibitor. Cellular assays are not typically performed with this compound as a direct cell-modulating agent, as its primary applications are in chiral chemistry and organic synthesis. The compound's tartaric acid scaffold allows for various chemical transformations. |
| ln Vivo |
In vivo data for (+)-di-p-toluoyl-D-tartaric acid is limited, as it is primarily a research reagent and chiral resolving agent. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Its primary applications are in chiral chemistry and organic synthesis. Specific in vivo data for the parent compound is not available in the public literature. The compound is not a therapeutic candidate.
|
| Enzyme Assay |
In vitro assays for (+)-di-p-toluoyl-D-tartaric acid typically evaluate its use as a chiral resolving agent. A standard protocol involves dissolving the compound in an appropriate solvent and adding it to a racemic mixture of the compound to be resolved. The diastereomeric salts formed are separated by crystallization. The enantiomeric excess of the resolved compound is determined by chiral HPLC or polarimetry. The compound's effectiveness as a resolving agent is evaluated by the yield and enantiomeric purity of the resolved product. Enzyme inhibition assays can be performed using standard protocols.
|
| Cell Assay |
Cellular assays for (+)-di-p-toluoyl-D-tartaric acid are not standard, as the compound is primarily used as a chiral resolving agent and enzyme inhibitor rather than as a cell-modulating agent. Any cellular studies would focus on evaluating the compound's enzyme inhibitory activity. A typical protocol would involve culturing appropriate cell lines in growth medium at 37°C with 5% CO₂. Cells would be treated with varying concentrations of the compound. Enzyme activity in cell lysates would be measured using appropriate substrates. Cell viability would be assessed using MTT or similar assays.
|
| Animal Protocol |
In vivo animal studies for (+)-di-p-toluoyl-D-tartaric acid are not standard, as it is a research reagent rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would be limited to toxicological evaluations of the compound as an industrial chemical. The compound's primary value lies in its use as a chiral resolving agent and enzyme inhibitor. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (+)-di-p-toluoyl-D-tartaric acid is limited, as it is primarily a research reagent. The compound has a molecular weight of 386.36 g/mol and a molecular formula of C₂₀H₁₈O₈. It is a solid at room temperature. As a tartaric acid derivative, it may undergo metabolic hydrolysis and conjugation. Specific ADME data is not available. The compound is stored in a dry, cool place.
|
| Toxicity/Toxicokinetics |
(+)-Di-p-toluoyl-D-tartaric acid is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values are available in the public domain.
|
| Additional Infomation |
(+)-Di-p-toluoyl-D-tartaric acid ((+)-Di-p-toluoyl-D-(+)-tartaric acid, CAS 32634-68-7) is a biochemical reagent with the molecular formula C₂₀H₁₈O₈. It is used as a chiral resolving agent and enzyme inhibitor. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes.
|
| Molecular Formula |
C20H18O8
|
|---|---|
| Molecular Weight |
386.35
|
| Exact Mass |
386.1
|
| CAS # |
32634-68-7
|
| Related CAS # |
(-)-Di-p-toluoyl-L-tartaric Acid;32634-66-5
|
| PubChem CID |
263211
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
626.5±55.0 °C at 760 mmHg
|
| Melting Point |
169-171 °C(lit.)
|
| Flash Point |
223.2±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| LogP |
6.74
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
28
|
| Complexity |
533
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=CC=C(C=C1)C(=O)O[C@@H]([C@@H](C(=O)O)OC(=O)C2=CC=C(C=C2)C)C(=O)O
|
| InChi Key |
CMIBUZBMZCBCAT-HOTGVXAUSA-N
|
| InChi Code |
InChI=1S/C20H18O8/c1-11-3-7-13(8-4-11)19(25)27-15(17(21)22)16(18(23)24)28-20(26)14-9-5-12(2)6-10-14/h3-10,15-16H,1-2H3,(H,21,22)(H,23,24)/t15-,16-/m0/s1
|
| Chemical Name |
(2S,3S)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5883 mL | 12.9416 mL | 25.8833 mL | |
| 5 mM | 0.5177 mL | 2.5883 mL | 5.1767 mL | |
| 10 mM | 0.2588 mL | 1.2942 mL | 2.5883 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
